Jessica Ritsick, Yifan Wang, Ph.D. Our FDA: Drug & Device Team analyzes the Food and Drug Administration’s new guidance on Bayesian approaches to innovative drug trials, providing greater clarity on ...
This is a guest post by Nathan Paxton. As social scientists, at least as regards what we can empirically assess, we tend to make statements of probability rather than fact. So rather than say that ...
New FDA guidance on the use of Bayesian statistics signals a broader shift in accommodating more flexible clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results